HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Frontera Therapeutics / Equity Capital Markets

<ul>
<li>Unlike gene therapy companies that heavily bet on CNS/systemic administration, Frontera's pipeline is highly concentrated in ophthalmology/cardiovascular diseases, which are the most mature and risk-controllable application areas of AAV technology.</li>
<li>Frontera has established commercial-scale production capacity for Bac/Sf9 insect cell system.This is one of the few mature paths that can reduce cost of rAAV, providing crucial flexibility for product pricing.</li>
<li>Post-Money valuation after Series B Financing was US$527 million. Under current conditions, there could be limited room for a significant premium in its IPO valuation over its Series B valuation.</li>
</ul>


Unlike gene therapy companies that heavily bet on CNS/systemic administration, Frontera's pipeline is highly concentrated in ophthalmology/cardiovascular diseases, which are the most mature and risk-controllable application areas of AAV technology.
Frontera has established commercial-scale production capacity for Bac/Sf9 insect cell system.This is one of the few mature paths that can reduce cost of rAAV, providing crucial flexibility for product pricing.
Post-Money valuation after Series B Financing was US$527 million. Under current conditions, there could be limited room for a significant premium in its IPO valuation over its Series B valuation.


Pre-IPO Frontera Therapeutics - The Promising Gene Therapy Pipeline and the Concerns Behind

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

<ul>
<li>Frontera, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. UBS and Haitong are the joint book runners.</li>
<li>In this note, we look at the company’s core product FT-003 and FT-002, and assess the selling point around the core products.</li>
<li>We also look at the company’s pre-IPO investors and management team.</li>
</ul>


Frontera, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. UBS and Haitong are the joint book runners.
In this note, we look at the company’s core product FT-003 and FT-002, and assess the selling point around the core products.
We also look at the company’s pre-IPO investors and management team.


Frontera Pre-IPO: Emerging Ophthalmic Gene Therapy Player with a Catch

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, the market didn't appear to be in a mood to for a customary slowdown at the start of the year.</li>
<li>On the placements front, issuers and shareholders have started the new year with a bang, with deals launched across regions.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, the market didn't appear to be in a mood to for a customary slowdown at the start of the year.
On the placements front, issuers and shareholders have started the new year with a bang, with deals launched across regions.


Aequitas: ECM Weekly (12 January 2026) - Biren, MiniMax, Gigadevice, Omnivision, Busy Ming, HPSP, GF

China

Frontera Therapeutics is a global, clinical-stage biotech company creating advanced AAV (adeno-associated virus) gene therapies for rare and common diseases, using their proprietary APEX platform for better vectors and a Suzhou GMP facility for low-cost, high-quality production.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Frontera Therapeutics (FRONT HK)

Pre-IPO Frontera Therapeutics - The Promising Gene Therapy Pipeline and the Concerns Behind

Frontera focuses on ophthalmology and cardiovascular diseases, boasting mature paths of cost reduction for rAAV. Due to risks on R&D...

Xinyao (Criss) Wang

Frontera Pre-IPO: Emerging Ophthalmic Gene Therapy Player with a Catch

China-based biotech company Frontera aims to raise $100 million through Hong Kong listing. We look at its core products FT-003 and FT-002, pre-IPO...

Ke Yan, CFA, FRM

Aequitas: ECM Weekly (12 January 2026) - Biren, MiniMax, Gigadevice, Omnivision, Busy Ming, HPSP, GF

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO Frontera Therapeutics - The Promising Gene Therapy Pipeline and the Concerns Behind

​Frontera focuses on ophthalmology and cardiovascular diseases, boasting mature paths of cost reduction for rAAV. Due to risks on R&D...

Xinyao (Criss) Wang

Frontera Pre-IPO: Emerging Ophthalmic Gene Therapy Player with a Catch

​China-based biotech company Frontera aims to raise $100 million through Hong Kong listing. We look at its core products FT-003 and FT-002, pre-IPO...

Ke Yan, CFA, FRM

Aequitas: ECM Weekly (12 January 2026) - Biren, MiniMax, Gigadevice, Omnivision, Busy Ming, HPSP, GF

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Frontera focuses on ophthalmology and cardiovascular diseases, boasting mature paths of cost reduction for rAAV. Due to risks on R&D...

China-based biotech company Frontera aims to raise $100 million through Hong Kong listing. We look at its core products FT-003 and FT-002, pre-IPO...